Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry

Diana Bilton, Noreen Caine, Steve Cunningham, Nicholas J Simmonds, Rebecca Cosgriff, Siobhán B Carr

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	The Lancet Respiratory Medicine
Early online date	4 May 2018
DOIs	https://doi.org/10.1016/S2213-2600(18)30192-9
Publication status	E-pub ahead of print - 4 May 2018

Access to Document

@article{e2e730907485453cb6424fc1559fcac6,

title = "Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry",

author = "Diana Bilton and Noreen Caine and Steve Cunningham and Simmonds, {Nicholas J} and Rebecca Cosgriff and Carr, {Siobh{\'a}n B}",

year = "2018",

month = may,

day = "4",

doi = "10.1016/S2213-2600(18)30192-9",

language = "English",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry

AU - Bilton, Diana

AU - Caine, Noreen

AU - Cunningham, Steve

AU - Simmonds, Nicholas J

AU - Cosgriff, Rebecca

AU - Carr, Siobhán B

PY - 2018/5/4

Y1 - 2018/5/4

U2 - 10.1016/S2213-2600(18)30192-9

DO - 10.1016/S2213-2600(18)30192-9

M3 - Article

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

ER -